磷霉素在耐药形势下的临床应用定位再评估
|
摘要
磷霉素是一种发现较早的天然抗生素,具有独特的抗菌作用机制,通过阻断细菌细胞壁合成的第一步,可以作用于革兰阳性菌和革兰阴性菌,是一种繁殖期快速杀菌剂,并且能够破坏细菌生物被膜或抑制其形成。近年来,在严峻的耐药形势下,磷霉素凭借其独特的抗菌作用机制、药代动力学特点及交叉耐药发生低等优势,成为被广泛研究和应用的抗生素,尤其是对于多重耐药菌,磷霉素作为重要的联合应用药物,临床应用定位越来越广泛。
Fosfomycin is an early discovered natural antibiotic with unique antimicrobial mechanism,by blocking the first step in the synthesis of bacterial cell wall,it can act on gram-positive bacteria and gram-negative bacteria,and is a rapid bactericide in reproductive period of bacteria and can destroy or inhibit formation of bacterial biofilm.In recent years,under the current severe drug resistance situation,fosfomycin has become a widely studied and applied antibiotic because of its unique antimicrobial mechanism,pharmacokinetic characteristics and low cross-resistance,especially for multidrug-resistant organisms,as an important combined used antibiotic,fosfomycin has been applied more and more widely in clinical practice.
Fosfomycin is an early discovered natural antibiotic with unique antimicrobial mechanism,by blocking the first step in the synthesis of bacterial cell wall,it can act on gram-positive bacteria and gram-negative bacteria,and is a rapid bactericide in reproductive period of bacteria and can destroy or inhibit formation of bacterial biofilm.In recent years,under the current severe drug resistance situation,fosfomycin has become a widely studied and applied antibiotic because of its unique antimicrobial mechanism,pharmacokinetic characteristics and low cross-resistance,especially for multidrug-resistant organisms,as an important combined used antibiotic,fosfomycin has been applied more and more widely in clinical practice.
引文
[1]Karlowsky JA,Denisuik AJ,Lagacé-Wiens PR,et al.In vitro activity of fosfomycin against Escherichia coli isolated from patients with urinary tract infection in Canada as part of the CANWARD surveillance study[J].Antimicrob Agents Chemother,2014,58(2):1252-1256.
[2]Sastry S,Doi Y.Fosfomycin:Resurgence of an old companion[J].J Infect Chemother,2016,22(5):273-280.
[3]Falagas ME,Vouloumanou EK,Samonis G,et al.Fosfomycin[J].Clin Microbiol Rev,2016,29(2):321-347.
[4]Roussos N,Karageorgopoulos DE,Samonis G,et al.Clinical significance of the pharmacokinetic and pharmacodynamic characteristics of fosfomycin for the treatment of patients with systemic infections[J].Int J Antimicrob Agents,2009,34(6):506-515.
[5]Falagas ME,Maraki S,Karageorgopoulos DE,et al.Antimicrobial susceptibility of multidrug-resistant(MDR)and extensively drug-resistant(XDR)Enterobacteriaceae isolates to fosfomycin[J].Int J Antimicrob Agents,2010,35(3):240-243.
[6]Falagas ME,Kastoris AC,Kapaskelis AM,et al.Fosfomycin for the treatment of multidrug-resistant,including extendedspectrum beta-lactamase producing,Enterobacteriaceae infections:a systematic review[J].Lancet Infect Dis,2010,10(1):43-50.
[7]许元元,曹小利,程莉,等.尿培养产ESBLs大肠埃希菌的耐药特点及对磷霉素的敏感性分析[J].蚌埠医学院学报,2016,41(3):380-382.
[8]田鹏鹏,朱丽莎,马青,等.磷霉素对尿路感染患者肠杆菌科细菌的敏感性分析[J].中华医院感染学杂志,2017,27(12):2664-2667.
[9]Kresken M,Pfeifer Y,Hafner D,et al.Occurrence of multidrug resistant to oral antibiotics among Escherichia coli urine isolated from outpatient departments in Germany:extendedspectrumβ-lactamases and the role of fosfomycin[J].Int J Antimicrob Agents,2014,44(4):295-300.
[10]Veve MP,Wagner JL,Kenney RM,et al.Comparison of fosfomycin to ertapenem for outpatient or step-down therapy of extended-spectrum beta-lactamase urinary tract infections[J].Int J Antimicrob Agents,2016,48(1):56-60.
[11]Landry J,Hurst H.The emerging threat from carbapenem-resistant Enterobacteriaceae[J].Nurs Womens Health,2013,17(6):519-524.
[12]史煜波,胡丽庆,翁幸鐾,等.磷霉素、米诺环素等抗生素对blaKPC-2肺炎克雷伯杆菌的体外药敏研究[J].中国微生态学杂志,2015,27(5):574-580.
[13]曹敏,黄林.磷霉素对肠杆菌科细菌的抗菌作用研究[J].浙江医学,2017,39(15):1277-1279.
[14]钱学深,夏文颖,梅亚宁,等.磷霉素联合亚胺培南对碳青霉烯类耐药肠杆菌科细菌的体外抗菌活性研究[J].中国临床药理学杂志,2016,32(2):156-158.
[15]Kaase M,Szabados F,Anders A,et al.Fosfomycin susceptibility in carbapenem-resistant Enterobacteriaceae from Germany[J].J Clin Microbiol,2014,52(6):1893-1897.
[16]郑海岚,华俊彦,朱雅艳,等.阿米卡星与磷霉素治疗产KPC酶细菌的疗效观察[J].中华医院感染学杂志,2014,24(12):2923-2924.
[17]黄娟娟,何鸽飞,易爱纯,等.磷霉素联合依替米星治疗耐碳青霉烯肺炎克雷伯菌重症感染的疗效[J].中南药学,2017,15(10):146-149.
[18]Pontikis K,Karaiskos I,Bastani S,et al.Outcomes of critically ill intensive care unit patients treated with fosfomycin for infections due to pandrug-resistant and extensively drug-resistant carbapenemase-producing gram-negative bacteria[J].Int J Antimicrob Agents,2014,43(1):52-59.
[19]Samonis G,Maraki S,Karageorgopoulos DE,et al.Synergy of fosfomycin with carbapenems,colistin,netilmicin,and tigecycline against multidrug-resistant Klebsiella pneumoniae,Escherichia coli,and Pseudomonas aeruginosa clinical isolates[J].Eur J Clin Microbiol Infect Dis,2012,31(5):695-701.
[20]贺吉童,陶静,倪文涛,等.多黏菌素E联合磷霉素对产碳青霉烯酶肺炎克雷伯菌的体外抗菌活性研究[J].中国药学杂志,2017,52(13):33-37.
[21]孙凤军,熊志坚,冯伟,等.磷霉素联合碳青霉烯类抗尿路感染耐药铜绿假单胞菌的体外协同作用研究[J].中国药房,2016,27(20):2765-2767.
[22]Kunakonvichaya B,Thirapanmethee K,Khuntayaporn P,et al.Synergistic effects of fosfomycin and carbapenems against carbapenem-resistant Pseudomonas aeruginosa clinical isolates[J].Int J Antimicrob Agents,2015,45(5):556-557.
[23]Apisarnthanarak A,Mundy LM.Use of high-dose 4-hour infusion of doripenem,in combination with fosfomycin,for treatment of carbapenem-resistant Pseudomonas aeruginosa pneumonia[J].Clin Infect Dis,2010,51(11):1352-1354.
[24]王秋菊,宋晓玉,全勇,等.磷霉素与妥布霉素联合应用对呼吸道感染常见菌的体外抗菌活性[J].检验医学与临床,2015,12(23):3479-3481.
[25]Montgomery AB,Rhomerg PR,Abuan T,et al.Potentiation effects of amikacin and fosfomycin against selected amikacinnonsusceptible Gram-negative respiratory tract pathogens[J].Antimicrob Agents Chemother,2014,58(7):3714-3719.
[26]Morrill HJ,Pogue JM,Kaye KS,et al.Treatment options for carbapenem-resistant Enterobacteriaceae infections[J].Open Forum Infect Dis,2015,2(2):ofv050.
[27]温汉春,陈一强,黄宏,等.磷霉素联合4种抗菌药物对泛耐药鲍氏不动杆菌体外活性研究[J].中华医院感染学杂志,2015,25(14):3199-3201.
[28]关卫,韩颖,胡艳敏,等.磷霉素钠联合用药对耐药鲍曼不动杆菌药物敏感性的实验研究[J].中华医院感染学杂志,2017,27(6):1215-1217.
[29]Sirijatuphat R,Thamlikitkul V.Preliminary study of colistin versus colistin plus fosfomycin for treatment of carbapenem-resistant Acinetobacter baumannii infections[J].Antimicrob Agents Chemother,2014,58(9):5598-5601.
[30]Falagas ME,Maraki S,Karageorgopoulos DE,et al.Antimicrobial susceptibility of Gram-positive non-urinary isolates to fosfomycin[J].Int J Antimicrob Agents,2010,35(5):497-499.
[31]胡文,邓国泉,伍婷,等.万古霉素单用与联用磷霉素治疗耐甲氧西林金黄色葡萄球菌肺部感染的疗效比较[J].实用中西医结合临床,2012,12(4):6-7.
[32]梁蓓蓓,李悦,牛卉,等.利奈唑胺与磷霉素对甲氧西林耐药金黄色葡萄球菌体外联合药敏的研究[J].中国临床药理学杂志,2015,31(18):1840-1842.
[33]del Rio A,Gasch O,Moreno A,et al.Efficacy and safety of fosfomycin plus imipenem as rescue therapy for complicated bacteremia and endocarditis due to methicillin-resistant Staphylococcus aureus:a multicenter clinical trial[J].Clin Infect Dis,2014,59(8):1105-1112.
[34]Correa AA,Pignatari AC,da Silverira M,et al.Small hospital matter:insights from the emergence and spread of vancomycin-resistant Enterococci in 2 public hospitals in inner Brazil[J].Diagn Microbiol Infect Dis,2015,82(3):227-233.
[35]Vardakas KZ,Legakis NJ,Triarides N,et al.Susceptibility of contemporary isolates to fosfomycin:a systematic review of the literature[J].Int J Antimicrob Agents,2016,47(4):269-285.
[36]王娜,谭然,刘琳,等.磷霉素联合常规抗菌药物对耐万古霉素肠球菌的体外抗菌活性影响[J].中华医院感染学杂志,2016,26(12):2664-2666.
[37]Guo Q,Ding B,JovéT,et al.Characterization of a Novel IncHI2 plasmid carrying tandem copies of blaCTX-M-2 in a fosA6-harboring Escherichia coli sequence type 410 strain[J].Antimicrob Agents Chemother,2016,60(11):6742-6747.
[38]Xu X,Chen C,Lin D,et al.The fosfomycin resistance gene fosB3is located on a transferable,extrachromosomal circular intermediate in clinical Enterococcus faecium isolates[J].PLoS One,2013,8(10):e78106.
[39]Ho PL,Chan J,Lo WU,et al.Prevalence and molecular epidemiology of plasmid-mediated fosfomycin resistance genes among blood and urinary Escherichia coli isolates[J].J Med Microbiol,2014,63(Pt 11):1707-1713.
[2]Sastry S,Doi Y.Fosfomycin:Resurgence of an old companion[J].J Infect Chemother,2016,22(5):273-280.
[3]Falagas ME,Vouloumanou EK,Samonis G,et al.Fosfomycin[J].Clin Microbiol Rev,2016,29(2):321-347.
[4]Roussos N,Karageorgopoulos DE,Samonis G,et al.Clinical significance of the pharmacokinetic and pharmacodynamic characteristics of fosfomycin for the treatment of patients with systemic infections[J].Int J Antimicrob Agents,2009,34(6):506-515.
[5]Falagas ME,Maraki S,Karageorgopoulos DE,et al.Antimicrobial susceptibility of multidrug-resistant(MDR)and extensively drug-resistant(XDR)Enterobacteriaceae isolates to fosfomycin[J].Int J Antimicrob Agents,2010,35(3):240-243.
[6]Falagas ME,Kastoris AC,Kapaskelis AM,et al.Fosfomycin for the treatment of multidrug-resistant,including extendedspectrum beta-lactamase producing,Enterobacteriaceae infections:a systematic review[J].Lancet Infect Dis,2010,10(1):43-50.
[7]许元元,曹小利,程莉,等.尿培养产ESBLs大肠埃希菌的耐药特点及对磷霉素的敏感性分析[J].蚌埠医学院学报,2016,41(3):380-382.
[8]田鹏鹏,朱丽莎,马青,等.磷霉素对尿路感染患者肠杆菌科细菌的敏感性分析[J].中华医院感染学杂志,2017,27(12):2664-2667.
[9]Kresken M,Pfeifer Y,Hafner D,et al.Occurrence of multidrug resistant to oral antibiotics among Escherichia coli urine isolated from outpatient departments in Germany:extendedspectrumβ-lactamases and the role of fosfomycin[J].Int J Antimicrob Agents,2014,44(4):295-300.
[10]Veve MP,Wagner JL,Kenney RM,et al.Comparison of fosfomycin to ertapenem for outpatient or step-down therapy of extended-spectrum beta-lactamase urinary tract infections[J].Int J Antimicrob Agents,2016,48(1):56-60.
[11]Landry J,Hurst H.The emerging threat from carbapenem-resistant Enterobacteriaceae[J].Nurs Womens Health,2013,17(6):519-524.
[12]史煜波,胡丽庆,翁幸鐾,等.磷霉素、米诺环素等抗生素对blaKPC-2肺炎克雷伯杆菌的体外药敏研究[J].中国微生态学杂志,2015,27(5):574-580.
[13]曹敏,黄林.磷霉素对肠杆菌科细菌的抗菌作用研究[J].浙江医学,2017,39(15):1277-1279.
[14]钱学深,夏文颖,梅亚宁,等.磷霉素联合亚胺培南对碳青霉烯类耐药肠杆菌科细菌的体外抗菌活性研究[J].中国临床药理学杂志,2016,32(2):156-158.
[15]Kaase M,Szabados F,Anders A,et al.Fosfomycin susceptibility in carbapenem-resistant Enterobacteriaceae from Germany[J].J Clin Microbiol,2014,52(6):1893-1897.
[16]郑海岚,华俊彦,朱雅艳,等.阿米卡星与磷霉素治疗产KPC酶细菌的疗效观察[J].中华医院感染学杂志,2014,24(12):2923-2924.
[17]黄娟娟,何鸽飞,易爱纯,等.磷霉素联合依替米星治疗耐碳青霉烯肺炎克雷伯菌重症感染的疗效[J].中南药学,2017,15(10):146-149.
[18]Pontikis K,Karaiskos I,Bastani S,et al.Outcomes of critically ill intensive care unit patients treated with fosfomycin for infections due to pandrug-resistant and extensively drug-resistant carbapenemase-producing gram-negative bacteria[J].Int J Antimicrob Agents,2014,43(1):52-59.
[19]Samonis G,Maraki S,Karageorgopoulos DE,et al.Synergy of fosfomycin with carbapenems,colistin,netilmicin,and tigecycline against multidrug-resistant Klebsiella pneumoniae,Escherichia coli,and Pseudomonas aeruginosa clinical isolates[J].Eur J Clin Microbiol Infect Dis,2012,31(5):695-701.
[20]贺吉童,陶静,倪文涛,等.多黏菌素E联合磷霉素对产碳青霉烯酶肺炎克雷伯菌的体外抗菌活性研究[J].中国药学杂志,2017,52(13):33-37.
[21]孙凤军,熊志坚,冯伟,等.磷霉素联合碳青霉烯类抗尿路感染耐药铜绿假单胞菌的体外协同作用研究[J].中国药房,2016,27(20):2765-2767.
[22]Kunakonvichaya B,Thirapanmethee K,Khuntayaporn P,et al.Synergistic effects of fosfomycin and carbapenems against carbapenem-resistant Pseudomonas aeruginosa clinical isolates[J].Int J Antimicrob Agents,2015,45(5):556-557.
[23]Apisarnthanarak A,Mundy LM.Use of high-dose 4-hour infusion of doripenem,in combination with fosfomycin,for treatment of carbapenem-resistant Pseudomonas aeruginosa pneumonia[J].Clin Infect Dis,2010,51(11):1352-1354.
[24]王秋菊,宋晓玉,全勇,等.磷霉素与妥布霉素联合应用对呼吸道感染常见菌的体外抗菌活性[J].检验医学与临床,2015,12(23):3479-3481.
[25]Montgomery AB,Rhomerg PR,Abuan T,et al.Potentiation effects of amikacin and fosfomycin against selected amikacinnonsusceptible Gram-negative respiratory tract pathogens[J].Antimicrob Agents Chemother,2014,58(7):3714-3719.
[26]Morrill HJ,Pogue JM,Kaye KS,et al.Treatment options for carbapenem-resistant Enterobacteriaceae infections[J].Open Forum Infect Dis,2015,2(2):ofv050.
[27]温汉春,陈一强,黄宏,等.磷霉素联合4种抗菌药物对泛耐药鲍氏不动杆菌体外活性研究[J].中华医院感染学杂志,2015,25(14):3199-3201.
[28]关卫,韩颖,胡艳敏,等.磷霉素钠联合用药对耐药鲍曼不动杆菌药物敏感性的实验研究[J].中华医院感染学杂志,2017,27(6):1215-1217.
[29]Sirijatuphat R,Thamlikitkul V.Preliminary study of colistin versus colistin plus fosfomycin for treatment of carbapenem-resistant Acinetobacter baumannii infections[J].Antimicrob Agents Chemother,2014,58(9):5598-5601.
[30]Falagas ME,Maraki S,Karageorgopoulos DE,et al.Antimicrobial susceptibility of Gram-positive non-urinary isolates to fosfomycin[J].Int J Antimicrob Agents,2010,35(5):497-499.
[31]胡文,邓国泉,伍婷,等.万古霉素单用与联用磷霉素治疗耐甲氧西林金黄色葡萄球菌肺部感染的疗效比较[J].实用中西医结合临床,2012,12(4):6-7.
[32]梁蓓蓓,李悦,牛卉,等.利奈唑胺与磷霉素对甲氧西林耐药金黄色葡萄球菌体外联合药敏的研究[J].中国临床药理学杂志,2015,31(18):1840-1842.
[33]del Rio A,Gasch O,Moreno A,et al.Efficacy and safety of fosfomycin plus imipenem as rescue therapy for complicated bacteremia and endocarditis due to methicillin-resistant Staphylococcus aureus:a multicenter clinical trial[J].Clin Infect Dis,2014,59(8):1105-1112.
[34]Correa AA,Pignatari AC,da Silverira M,et al.Small hospital matter:insights from the emergence and spread of vancomycin-resistant Enterococci in 2 public hospitals in inner Brazil[J].Diagn Microbiol Infect Dis,2015,82(3):227-233.
[35]Vardakas KZ,Legakis NJ,Triarides N,et al.Susceptibility of contemporary isolates to fosfomycin:a systematic review of the literature[J].Int J Antimicrob Agents,2016,47(4):269-285.
[36]王娜,谭然,刘琳,等.磷霉素联合常规抗菌药物对耐万古霉素肠球菌的体外抗菌活性影响[J].中华医院感染学杂志,2016,26(12):2664-2666.
[37]Guo Q,Ding B,JovéT,et al.Characterization of a Novel IncHI2 plasmid carrying tandem copies of blaCTX-M-2 in a fosA6-harboring Escherichia coli sequence type 410 strain[J].Antimicrob Agents Chemother,2016,60(11):6742-6747.
[38]Xu X,Chen C,Lin D,et al.The fosfomycin resistance gene fosB3is located on a transferable,extrachromosomal circular intermediate in clinical Enterococcus faecium isolates[J].PLoS One,2013,8(10):e78106.
[39]Ho PL,Chan J,Lo WU,et al.Prevalence and molecular epidemiology of plasmid-mediated fosfomycin resistance genes among blood and urinary Escherichia coli isolates[J].J Med Microbiol,2014,63(Pt 11):1707-1713.